Literature DB >> 11317241

A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation.

M Offidani1, L Corvatta, A Olivieri, A Mele, M Brunori, M Montanari, S Rupoli, P Scalari, P Leoni.   

Abstract

Varicella-zoster virus (VZV) frequently causes severe infections in patients who have undergone bone marrow transplantation. The frequency of, characteristics of, and risk factors for this infection were studied in 164 patients undergoing autologous peripheral blood progenitor cell transplantation (PBPCT). Twenty-six patients (15.8%) developed VZV infection, and the actuarial risk was 10% at 1 year. No patient had visceral dissemination or died because of VZV, although one-third of the patients developed postherpetic neuralgia. By multivariate analysis, a CD4(+) lymphocyte count of <200 cells/microL (P<.0001; odds ratio [OR], 2.0) and a CD8(+) lymphocyte count of <800 cells/microL (P=.0073; OR, 2.0) at day 30 after transplantation were factors associated with VZV infection. Patients with both these adverse factors had an actuarial risk of VZV of 48% at 1 year. Patients with deficiency in both CD4(+) and CD8(+) lymphocytes are at high risk of VZV infection. These patients should be considered as candidates for preventive therapy, but whether for antiviral therapy or vaccination remains to be investigated.

Entities:  

Mesh:

Year:  2001        PMID: 11317241     DOI: 10.1086/320157

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.

Authors:  Kareem Jamani; Judy MacDonald; Martin Lavoie; Tyler S Williamson; Christopher B Brown; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Peter Duggan; Jason Tay; Douglas Stewart; Andrew Daly; Jan Storek
Journal:  Blood Adv       Date:  2016-11-30

2.  Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.

Authors:  Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan
Journal:  JAMA       Date:  2019-07-09       Impact factor: 56.272

3.  A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.

Authors:  Edward A Stadtmauer; Keith M Sullivan; Francisco M Marty; Sanjeet S Dadwal; Genovefa A Papanicolaou; Thomas C Shea; Sherif B Mossad; Charalambos Andreadis; Jo-Anne H Young; Francis K Buadi; Mohamed El Idrissi; Thomas C Heineman; Elchonon M Berkowitz
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

4.  Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.

Authors:  C Kamber; S Zimmerli; F Suter-Riniker; B U Mueller; B M Taleghani; D Betticher; T Zander; T Pabst
Journal:  Bone Marrow Transplant       Date:  2015-01-19       Impact factor: 5.483

5.  Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation.

Authors:  Koji Kawamura; Jin Hayakawa; Yu Akahoshi; Naonori Harada; Hirofumi Nakano; Kazuaki Kameda; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Kana Sakamoto; Masahiro Ashizawa; Miki Sato; Kiriko Terasako-Saito; Shun-Ichi Kimura; Misato Kikuchi; Hideki Nakasone; Rie Yamazaki; Junya Kanda; Shinichi Kako; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2015-05-20       Impact factor: 2.319

6.  Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents.

Authors:  Alhossain Khalafallah; Matthias Maiwald; Amanda Cox; Denise Burns; Gerald Bates; Terry Hannan; David Seaton; Bernadene Fernandopulle; Damien Meagher; Terry Brain
Journal:  Mediterr J Hematol Infect Dis       Date:  2010-04-20       Impact factor: 2.576

7.  Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice.

Authors:  Edward A Stadtmauer; Keith M Sullivan; Mohamed El Idrissi; Bruno Salaun; Aránzazu Alonso Alonso; Charalambos Andreadis; Veli-Jukka Anttila; Adrian Jc Bloor; Raewyn Broady; Claudia Cellini; Antonio Cuneo; Alemnew F Dagnew; Emmanuel Di Paolo; HyeonSeok Eom; Ana Pilar González-Rodríguez; Andrew Grigg; Andreas Guenther; Thomas C Heineman; Isidro Jarque; Jae-Yong Kwak; Alessandro Lucchesi; Lidia Oostvogels; Marta Polo Zarzuela; Anne E Schuind; Thomas C Shea; Ulla Marjatta Sinisalo; Filiz Vural; Lucrecia Yáñez San Segundo; Pierre Zachée; Adriana Bastidas
Journal:  Hum Vaccin Immunother       Date:  2021-08-18       Impact factor: 3.452

8. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

Review 9.  Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview.

Authors:  Alemnew F Dagnew; Peter Vink; Mamadou Drame; David O Willer; Bruno Salaun; Anne E Schuind
Journal:  Hum Vaccin Immunother       Date:  2021-06-30       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.